Abstract: Provided herein is a method for one or mor of preventing, treating, reducing the severity of acute respiratory distress syndrome (ARDS) in a subject at risk for contracting ARDS and infected with a coronavirus or SARS-CoV-2, comprising administering to the subject metformin, an analog or a derivative thereof, thereby preventing, treating, or reducing the severity of ARDS in the subject.

Abstract: Provided herein are methods of treating macrophage-mediated inflammatory diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.

Abstract: Provided herein are methods and compositions for treating cancer through a combination of an inhibitor of macropinocytosis upregulation and an autophagy inhibitor. Also provided are methods and compositions for inducing cell death of cancer cells, and transgenic animal models regarding same.

Abstract: Provided herein is a method for one or mor of preventing, treating, reducing the severity of acute respiratory distress syndrome (ARDS) in a subject at risk for contracting ARDS and infected with a coronavirus or SARS-CoV-2, comprising administering to the subject metformin, an analog or a derivative thereof, thereby preventing, treating, or reducing the severity of ARDS in the subject.

Abstract: Provided herein are methods for treating a disease or condition associated with one or more of: mtDNA fragmentation; cytostolic Ox-mtDNA; mtDNA release; or Casp1 activation and IL-1? production by administering an effective amount of an inhibitor of human flap endonuclease-1 (FEN1). These diseases include without limitation, an inflammatory or a neurodegenerative disease, such as Alzheimer's, disease, Parkinson's disease, atherosclerosis, NASH, asthma, inflammatory bowel disease, melanoma, metabolic pathologies, including obesity, type 2 diabetes, atherosclerosis, inflammatory bowel diseases, gout, and periodic fevers.

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.

Abstract: Provided herein are prognostic methods for determining median survival of subjects from a cancer such as a desmoplastic cancer, a fibrolytic cancer or a pancreatic ductal adenocarcinoma (PDAC) as well as methods for treating same.

Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.

Abstract: Provided herein are methods and compositions for treating cancer through a combination of an inhibitor of macropinocytosis upregulation and an autophagy inhibitor. Also provided are methods and compositions for inducing cell death of cancer cells, and transgenic animal models regarding same.

Abstract: Provided herein are methods of treating macrophage-mediated inflammatory diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.

Abstract: Provided herein are methods of inducing expression of major histocompatibility complex (MHC) molecules on a cancer cell surface by inducing expression of one or more genes associated with MHC. Also disclosed are methods of screening for agents useful in treating cancer and methods of treating such cancers.

Abstract: The invention provides purified mammalian hybrid hepatocyte (HybHP) cells, compositions comprising HybHP cells, methods for purifying HybHP cells, methods for in vitro culture of HybHP cells, and methods for using HybHP cells to repopulate and/or treat the liver of a subject in need thereof.

Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.

Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.

Abstract: The invention provides a method for treating cancer in a subject in need thereof, wherein said subject comprises cancer tissue that ‘contains epithelial cancer cells and immunosuppressive 8 cells, and wherein said method comprises administering to said subject a therapeutically effective amount of a) one or more first composition that pauses—immunogenic eel’ death and/or of said epithelial cancer cells, and b) one or more second composition that reduces one or both of the number and function of said immunosuppressive B cells in said cancer.

Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.

Abstract: Provided herein are methods of treating nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and/or elevated de novo lipogenesis (DNL) by inhibiting caspase-2 activity or expression. Also disclosed are methods of screening for agents useful in such methods.